Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the symbol lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now X
Title: Waters Corporation Q2 2010 Earnings Call Transcript
Call Start: 8:30
Call End: 9:30
Waters Corporation (WAT)
Q2 2010 Earnings Call
July 28, 2010 8:30 a.m. ET
Douglas Berthiaume - Chairman, President & CEO
John Ornell, Waters Chief Financial Officer
Art Caputo, President of the Waters Division
Gene Cassis, Vice President of Investor Relations.
Quintin Lai - Robert W. Baird
Tycho Peterson - JPMorgan
Ross Muken - Deutsche Bank
Ahmet Bala - Citigroup
Marshall Urist – Morgan Stanley
Paul Knight – CLSA
Jon Groberg - Macquarie Capital
Jon Wood - Jefferies
Derik De Bruin - UBS
Doug Schenkel - Cowan & Company
John Sullivan – Leerink Swann
Steve Willoughby – Cleveland Research
Previous Statements by WAT
» Waters Corp. Q1 2010 Earnings Call Transcript
» Waters Corporation Q4 2009 Earnings Call Transcript
» Waters Corporation Q3 2009 Earnings Call Transcript
Thank you. Good morning and welcome to the Waters Corporation second quarter financial results conference call. With me on today’s call is John Ornell, the Waters Chief Financial Officer; Art Caputo, President of the Waters Division and Gene Cassis, the Vice President of Investor Relations.
As is our normal practice I’m going to start with an overview of the quarter’s highlights. John will follow with details on our financial results and provide you with our outlook for the third quarter and for the full year, but before we get to that, I’d like John to cover the cautionary language.
During the course of this conference call we will make various forward-looking statements regarding future events or future financial performance of the company. In particular, we will provide guidance regarding future income statement results of the company, this time for Q3 and full-year 2010. We caution you that all such statements are only predictions and that actual events or results may differ materially.
For a detailed discussion of some of the risks and contingencies that could cause our actual performance to differ significantly from our present expectations, see our 10-K annual report for the fiscal year ended December 31, 2009 in part one under the caption business risk factors.
We further caution you that the company does not obligate or commit itself by providing this guidance to update predictions. We do not plan to update predictions regarding possible future income statement results except during our regularly scheduled quarterly earnings release conference calls and webcasts. The next earnings release call and webcast is currently planned for October 2010.
During this call we will refer to certain non-GAAP financial measures. A reconciliation of the non-GAAP financial measure to the most directly comparable GAAP measure is attached to the company’s earnings release issued this morning.
In our discussions of the results of operations we may refer to pro forma results which exclude the impact of items such as those outlined in our schedule entitled Reconciliation of Net Income per Diluted Share included in this morning’s press release.
Thank you John. Well from many perspectives I think we’re pleased with our second quarter’s performance. Sales of our newly introduced instrument systems and a broad-based improvement in customer demand contributed to 9% currency neutral sales growth and close to 20% growth in earnings per share. At the same time, we are confident that our exciting new product launches, which we showcased at June’s ASMS conference and earlier this year, will provide us with a powerful competitive edge in the second half of 2010 and further into 2011.
When you look at the quarter, sales growth to pharmaceutical and industrial chemical customers significantly improved in comparison to what we’ve been seeing in the last few quarters. As you know, the pharmaceutical segment represents more than half of the Waters Division’s sales, and it was improvements in this customer set that contributed most meaningfully to the division’s growth in the second quarter.
Geographically, pharmaceutical growth was strongest in North America and Asia, with drug discovery and QC applications leading the way. Sales in the quarter for most of our large-cap drug accounts grew sequentially from the levels that we saw in the first quarter. However, in absolute terms, demand remained somewhat weak, as many of these customers continue to rationalize their operations. Fortunately, strong demand from generic, specialty biopharmaceuticals, and TRO customers much more than offset the slower sales at our larger drug firms and all in our pharmaceutical business segment enjoyed double-digit top-line growth in the quarter.
Sales to industrial chemical accounts were also strong in the quarter, and our TA instruments division benefitted from a significant and broad rebound in capital spending. As you may recall, TA’s largest customer segment is the industrial chemical market, manufacturers of fine chemicals and polymers used in applications ranging from consumer electronics, to aerospace components, to medical devices. And as you may remember, the severe economic conditions that we endured in late 2008 and through 2009 resulted in a pronounced decline in TA’s sales.
Throughout this difficult period, TA continued to maintain its technological leadership, provided market-leading customer support, and successfully maintained system pricing. This year, as we continue to emerge from a recession, we are seeing a very impressive rebound in demand for both instrumentation and services at our TA division.
Within the Waters division, we are seeing a similar recovery in demand at fine chemical accounts, though this customer segment is a significantly smaller percentage of the Waters division’s overall business.
If you look at our non-profit customers, the combined government and academic sales grew more modestly in the quarter and were highlighted by robust shipment volume of high-end mass spec systems to universities.